{"id":1166,"date":"2020-08-26T09:33:21","date_gmt":"2020-08-26T09:33:21","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/new-genes-responsible-for-alzheimers-among-african-americans-identified\/"},"modified":"2021-01-08T11:09:53","modified_gmt":"2021-01-08T11:09:53","slug":"new-genes-responsible-for-alzheimers-among-african-americans-identified","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/new-genes-responsible-for-alzheimers-among-african-americans-identified\/","title":{"rendered":"New genes responsible for Alzheimer\u2019s among African Americans identified"},"content":{"rendered":"

Researchers have identified two new genetic risk factors for Alzheimer\u2019s disease (AD) among African Americans.  The findings may lead to the development of new therapies specifically targeting those genes.<\/p>\n

Despite the fact that AD is more common in African Americans than Caucasians, the AD genetic risk profile for African Americans is more poorly understood. While more than 20 genes have been identified as risk factors for AD in Caucasians, fewer than five have been identified for African Americans.<\/p>\n

In 2013, a genome-wide association study of AD in more than 5,500 African Americans identified two genetic risk factors for AD. This study looked at genetic variants across subjects\u2019 entire genome and compared their frequency in cases versus controls. Researchers from Boston University School of Medicine (BUSM) used these same subjects, but added additional AD risk information (smoking status, diabetes status, education level) to their statistical modelling to increase the power of the study. By doing so they were able to identify two new genes (COBL and SLC10A2) associated with risk of AD in African Americans.<\/p>\n

Mez_Jesse-432×636-2\u201cThere are currently no medications for AD that slow or stop the progression of the disease. Genes that increase risk for AD are potential targets for new disease-modifying AD drug therapies. Our study identifies two potentially \u201cdrugable\u201d targets,\u201d explains corresponding author Jesse Mez, MD, MS, assistant professor of neurology  and associate director of the BU Alzheimer\u2019s Disease & CTE Center Clinical Core.<\/p>\n

According to the researchers the methodology they employed for this study allowed them to make an important discovery without investing more money in genotyping or more effort to recruit volunteers. They believe that a similar methodology could be used for many other diseases to make new genetic discoveries without new large investments.<\/p>\n

\u201cDespite the fact that Alzheimer\u2019s disease is more common in African Americans than Caucasians, we understand less about the genes that influence risk of Alzheimer\u2019s in African Americans. Our hope is that this study begins to eliminate that disparity and that ultimately these newly identified genes become targets for Alzheimer\u2019s disease drug development,\u201d added Mez.<\/p>\n

Boston University Medical Center\nwww.bumc.bu.edu\/busm\/2016\/10\/25\/new-genes-responsible-for-alzheimers-among-african-americans-identified\/<\/link>\n","protected":false},"excerpt":{"rendered":"

Researchers have identified two new genetic risk factors for Alzheimer\u2019s disease (AD) among African Americans.  The findings may lead to the development of new therapies specifically targeting those genes. Despite the fact that AD is more common in African Americans than Caucasians, the AD genetic risk profile for African Americans is more poorly understood. While […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1166"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=1166"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1166\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=1166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=1166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=1166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}